Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

This study tests a targeted lung cancer drug called sunvozertinib given before and after surgery for patients with a specific genetic mutation (EGFR exon 20 insertion) in non-small cell lung cancer (NSCLC). **You may be eligible if...** - You are 18 or older with confirmed non-small cell lung cancer (stage II, IIIA, or IIIB) - Your tumor has a specific gene change called an EGFR exon 20 insertion mutation - Your cancer is considered operable (can be surgically removed) - You are in good general health (ECOG performance status 0-1) **You may NOT be eligible if...** - Your cancer has already spread to other parts of the body - You have previously received EGFR-targeted therapy - You have had prior chemotherapy or radiation for this cancer - You have active autoimmune disease or serious heart conditions Talk to your doctor to see if this trial is right for you.